This CPB has been revised to state that carfilzomib (Kyprolis) is considered medically necessary as an additional regimen in the criteria for initial approval for the treatment of multiple myeloma when used in combination with isatuximab-irfc and dexamethasone when the member has received at least one prior therapy.